ReviewFrontiers in immunology2026
Towards epigenetically informed and biobank-driven precision immunotherapy in melanoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma (CM) is a highly immunogenic and therapeutically intricate solid tumor, exemplifying the interactions between tumors and the immune system. Despite the significant enhancement in survival rates for patients with advanced melanoma due to immune checkpoint inhibitors (ICIs), numerous patients either exhibit resistance to these agents or develop immune evasion mechanisms. This underscores the pressing necessity to identify biological determinants of drug responses. A significant body of research indicates that epigenetic alterations, including DNA methylation, histone modifications, and ATP-dependent chromatin remodeling, are essential in modulating melanoma immunogenicity. This encompasses the modulation of antigen presentation, innate immune detection, interferon (IFN) signaling, melanoma plasticity, and the reconfiguration of the immune microenvironment. Furthermore, in contrast to genetic mutations, these mechanisms are reversible, positioning melanoma as a prime example of epigenetically regulated and potentially therapeutically targeted immune resistance. This review examines the novel insight that epigenetic therapies can enhance the immunological activity of "cold" or immune-excluded melanomas, transforming them into inflamed, drug-responsive tumors. This is achievable by restoring antigenicity and reactivating IFN-related pathways, leading to enhanced immune cell infiltration. The paper also addresses the necessity of longitudinal biobanking combined with integrated multi-omics analyses of epigenomics, transcriptomics, proteomics, and spatial profiling to investigate dynamic tumor-immune configurations, support the validation of candidate biomarkers, and explore biologically informed patient stratification. In conclusion, we propose an integrative model connecting epigenetic vulnerability, immune reconfiguration, and biobank-driven systems biology. This model is proposed as a research framework for investigating future biomarker informed immunotherapy strategies in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.